康缘药业：实际控制人肖伟增持32.52万元

Core Viewpoint - The actual controller and director of Kangyuan Pharmaceutical, Xiao Wei, increased his shareholding through a centralized bidding method on the Shanghai Stock Exchange, indicating confidence in the company's future prospects [1] Group 1: Shareholding Details - Xiao Wei purchased 20,000 shares for a total amount of 325,200 yuan, which represents 0.0035% of the company's total share capital [1] - Prior to the purchase, Xiao Wei held 17,003,200 shares, accounting for 3.0033% of the total shares [1] - After the increase, Xiao Wei and his concerted parties collectively hold 208 million shares, which is 36.6859% of the total shares [1] Group 2: Regulatory Compliance - The share increase does not trigger the obligation to report changes in equity and does not lead to a change in the controlling shareholder or actual controller [1] - Jiangsu Century Tongren Law Firm provided a special verification opinion confirming compliance with regulations [1]